Thank you ohm20 for the detailed explanation. As a scientific nitwit, is this more or less encouraging than your previous analysis?

I understood you thought a PD-1 inhibitor would be a good combo with leronlimab, so does this information make that more or less significant and/or more information needed?

I invested in leronlimab for cancer pre-COVID, so for my non-medical background this is one of the most encouraging information I can recall. Once MOA is proven, I would think every BP will be standing in line to submit their partnership proposal or BO offer.